Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Adaptive Biotechnologies Corp is a biotechnology business based in the US. Adaptive Biotechnologies shares (ADPT) are listed on the NASDAQ and all prices are listed in US Dollars. Adaptive Biotechnologies employs 858 staff and has a trailing 12-month revenue of around $159.7 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $7.12 |
|---|---|
| 52-week range | $5.96 - $37.55 |
| 50-day moving average | $9.57 |
| 200-day moving average | $12.68 |
| Wall St. target price | $13.17 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.63 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $7.12 from 2022-09-28
| 1 week (2022-09-22) | 3.19% |
|---|---|
| 1 month (2022-08-29) | -26.52% |
| 3 months (2022-06-29) | -13.38% |
| 6 months (2022-03-25) | -44.11% |
| 1 year (2021-09-29) | -78.07% |
|---|---|
| 2 years (2020-09-29) | -85.18% |
| 3 years (2019-09-27) | 30.31 |
| 5 years (2017-09-25) | N/A |
| Revenue TTM | $159.7 million |
|---|---|
| Gross profit TTM | $91 million |
| Return on assets TTM | -15.86% |
| Return on equity TTM | -38.33% |
| Profit margin | -145.37% |
| Book value | $3.63 |
| Market capitalisation | $933 million |
TTM: trailing 12 months
We're not expecting Adaptive Biotechnologies to pay a dividend over the next 12 months.
Over the last 12 months, Adaptive Biotechnologies's shares have ranged in value from as little as $5.955 up to $37.55. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adaptive Biotechnologies's is 0.9532. This would suggest that Adaptive Biotechnologies's shares are less volatile than average (for this exchange).
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
We’ve rounded up stats on some of the most popular wheat stocks, along with information on how these stocks compare and how to invest.
